Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Investor Presentation (November 2024)
11 slides from Vitrolife Ab's investor presentation, November 2024
Slide 1: Vitrolife AB (publ)
Vitrolife AB (publ) November 2024
Slide 2: Mission and global presence
Integrity Mission Be the leading global partner in reproductive health, Quality striving for better treatment outcomes for patients Global presence in Employees Sales in 2023 Innovation 125 markets ~ 1,100 3,512 MSEK Collaboration 2
Slide 3: Well balanced global company with strong market presence
Well balanced global company with strong market presence Net sales of 2,650 MSEK (Jan-Sep 2024) Consumables APAC Americas 39% 31% 32% Genetics Present in 42% Revenue by Revenue by countries representing geography business area 94% of global IVF treatments ~90% of sales from EMEA Technologies run rat
Slide 4: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining 5-7% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years *Source: World Health Orga
Slide 5: Key IVF market dynamics – How can we bring value to the ecosystem
Key IVF market dynamics – How can we bring value to the ecosystem Growth in demand Increase IVF capacity and accessibility Clinics labour and skills shortage Automation and digitalisation Consolidation of clinics Standardisation and scalability Diverse portfolio to address differences in Regionalisa
Slide 6: Corporate Strategy Vitrolife Group
Corporate Strategy Vitrolife Group Labour Our values Market Growth in Consoli- Regionali- Patient and skills megatrends demand shortage dation sation Empowerment Integrity Vision with a purpose Long-term growth and profit-targets (5 years) ”Enable people to fulfil the dream of having a healthy baby” A
Slide 7: Sustainability strategy: grounded in our values, driven by our mission
Sustainability strategy: grounded in our values, driven by our mission Sustainability strategy Purpose-driven growth Mission Be the leading global Ethical profitability partner in reproductive health, striving for better Planet accountability treatment outcomes for patients Inclusive engagement Integ
Slide 8: Sales and growth per geographical segment
Sales and growth per geographical segment January – September 2024 Americas EMEA APAC Total Organic growth* -2% +6% +7% +4% Sales (MSEK) 837 993 820 2,650 Share of total sales 32% 37% 31% 8 * Organic growth in local currencies
Slide 9: Financials January - September 2024
Financials January - September 2024 Sales Organic growth Gross margin 2,650 MSEK +4% 58.6% (2,607 MSEK) +2% in SEK In local currencies (56.1%) EBITDA Operating cash flow Net debt / EBITDA 888 MSEK 640 MSEK 0.8 Margin 33.5% (32.3%) (1.1) (586 MSEK) Earnings per share 2.76 SEK (2.42 SEK) 9
Slide 10: Contact: Patrik Tolf, CFO
Contact: Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21
Slide 11: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there